Maravai Lifesciences Holdings (MRVI) Equity Average (2021 - 2026)

Maravai Lifesciences Holdings' Equity Average history runs 6 years deep, the most recent figure standing at $290.7 million for Q1 2026.

• In Q1 2026, Equity Average fell 47.5% year-over-year to $290.7 million; the TTM figure through Mar 2026 stood at $290.7 million (down 47.5% YoY), while the FY2025 annual figure was $394.8 million, down 42.24% from the prior year.
• Equity Average was $290.7 million for Q1 2026 at Maravai Lifesciences Holdings, down from $322.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $902.9 million in Q1 2023 to a low of $290.7 million in Q1 2026.
• Historically, Equity Average has averaged $676.2 million across 5 years, with a median of $714.0 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Equity Average soared 225.49% in 2022, then plunged 47.5% in 2026.
• A 5-year view of Equity Average shows it stood at $873.5 million in 2022, then dropped by 3.71% to $841.1 million in 2023, then retreated by 29.26% to $595.0 million in 2024, then slumped by 45.86% to $322.1 million in 2025, then slipped by 9.74% to $290.7 million in 2026.
• The last three Equity Average figures came in at $290.7 million (Q1 2026), $322.1 million (Q4 2025), and $449.9 million (Q3 2025), per Business Quant data.